Euronext, the first and largest pan-European stock exchange in the Eurozone, launched its fourth session of TechShare, the only European programme for non-listed companies dedicated to IPOs. The programme is an educational network designed to help fast-growing European tech companies understand the role of capital markets and how these high-potential businesses can help them reach the next stage…
SOM Biotech joins Euronext TechShare Programme
posted on October 23, 2018
Workshop on Transfer of Scientific Knowledge in Duchenne Muscular Dystrophy
posted on September 25, 2018
The 3rd Workshop on the Transfer of Scientific Knowledge in Duchenne Muscular Dystrophy was held on September 7, 2018, coinciding with the World Duchenne Awareness Day. The workshop was organized by Duchenne Parent Project España and was focused on the research of the Muscular Dystrophies of Duchenne and Becker in Spain. Participants gathered at the Faculty of Biology of…
World Duchenne Awareness Day 2018
posted on September 10, 2018
September 7 is World Duchenne Awareness Day. In celebration of this awareness-raising event, SOM Biotech goes casual at the office and joins the "Jeans Day" campaign of Parent Project Muscular Dystrophy. SOM Biotech team Duchenne muscular dystrophy is the most common muscular dystrophy in children. It is a progressive disorder that causes muscles to become…
SOM Biotech at BIT’s 16th Annual Congress of International Drug Discovery Science and Technology 2018
posted on August 29, 2018
BIT's 16th Annual Congress of International Drug Discovery Science and Technology (IDDST 2018) was held on 16th-18th August 2018 in Boston, Massachusetts with the theme "Rethinking the Next Big Things in Pharma Innovations". The congress hosted leading scientists and professionals from the academia and industry worldwide, to discuss the latest developments in drug discovery and therapy. SOM Biotech CEO…
First patient recruited to SOMCT02 Huntington’s disease trial
posted on August 27, 2018
The SOMCT02 trial has recruited its first patient on 8th August 2018 at the Hospital Clínic de Barcelona, under the leadership of Dr. Esteban Muñoz. This indicates that the trial is now fully underway. SOMCT02 is a Phase 2a proof-of-concept and is designed as a randomized, double-blind, placebo-controlled, 2-arm, 27-week study to evaluate the safety and efficacy of…
SOM Biotech Announces Initiation of Phase 2a Clinical Trial of SOM3355 in Huntington’s Disease Patients
posted on July 17, 2018
BARCELONA, Spain and CAMBRIDGE, Massachusetts, July 17, 2018 -- SOM Biotech, a clinical-stage biopharmaceutical company that discovers and develops drugs for orphan indications in the Central Nervous System, has announced today the successful initiation of Phase 2a clinical trial of its repurposed compound SOM3355 for the treatment of the chorea movements associated to Huntington's disease. The Principal Investigator of the study is…